Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma

Z V Amoev; A V Alyasova; T N Gorshkova; E I Samsonova; E V Strokina; K N Kontorshchikova

doi:10.17691/stm2020.12.2.05

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma

Sovrem Tekhnologii Med. 2020;12(2):43-47. doi: 10.17691/stm2020.12.2.05.

Authors

Z V Amoev¹, A V Alyasova², T N Gorshkova³, E I Samsonova⁴, E V Strokina⁴, K N Kontorshchikova⁵

Affiliations

¹ Urologist, Department of Urology No.2, Clinical Hospital No.1, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
² Professor, Department of Oncology, Radiation Therapy and Radiology, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
³ Head of Clinical Diagnostic Laboratory, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
⁴ Physician, Clinical Diagnostic Laboratory, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
⁵ Professor, Head of the Department of Clinical Laboratory Diagnostics, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

Abstract

The aim of the study was to assess the possibility of using plasma levels of tumor M2-pyruvate kinase (Tu M2-PK), matrix carbonic anhydrase IX (CA9), and matrix metalloproteinase 9 (MMP9) in patients with renal cell cancer as predictors of the disease course and the response to treatment.

Materials and methods: Samples of blood plasma or serum of 46 patients with clear cell renal cancer T_1-4N_0-1M_0-1 obtained before surgery and 8-9 days after surgery were tested. The control group consisted of 20 practically healthy individuals, comparable in age with the examined patients. Quantitative determination of Tu M2-PK in EDTA-added blood plasma was performed by enzyme-linked immunosorbent assay using a ScheBo Tumor M2-PK test (Germany). Determination of CA9 by ELISA was performed using a Human Carbonic Anhydrase IX Quantikine ELISA Kit (USA) and MMP9 - using a Quantikine ELISA Kit (USA).

Results: In patients with renal cell carcinoma, a statistically significant increase in the level of Tu M2-PK, CA9 and a statistically significant decrease in MMP9 in comparison with the control group were found. The level of Tu M2-PK in patients with localized kidney cancer was significantly lower than in patients with disseminated cancer. An increase in size of the primary tumor and a decrease in the degree of its differentiation correlated with an increase in Tu M2-PK, and decrease in CA9 and MMP9 in the blood serum. Performing surgery equivalent to nephrectomy did not change the Tu M2-PK levels in the early postoperative period, but caused a decrease in the levels of CA9 and MMP9.

Conclusion: The results indicate a potential significance of Tu M2-PK, CA9, and MMP9 as biological markers for predicting the disease course in patients with renal cell carcinoma.

Keywords: markers of renal cell carcinoma; matrix carbonic anhydrase IX; metalloproteinase 9; renal cell carcinoma; tumor M2-pyruvate kinase.